severe acute pain how oliceridine works oliceridine development trv027 trv027 development trv734 trv250 platform what is a biased ligand trevena s able platform history of biased ligands investors investor relations press releases investor presentations analyst coverage corporate governance management board of directors committee composition contact the board financials & filings sec filings annual reports and proxies quarterly results stock information historic stock lookup investment calculator investor faqs contact us publications all publications oliceridine publications trv027 publications biased ligand publications contact contact directions to trevena trevena inc. nasdaq trvn is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of gpcr targeted medicines recent news 8 10 16 trevena to present at the 2016 wedbush pacgrow healthcare conference 8 4 16 trevena reports second quarter 2016 financial results and provides corporate update 6 16 16 trevena to present at the jmp life sciences conference we have identified three product candidates as potential best in class or first in class therapies for patients suffering from serious unmet medical needs . oliceridine trv130 iv for moderate to severe acute pain phase 3 trv734 oral for moderate to severe acute and chronic pain phase 1 trv250 oral for migraine preclinical about trevena management board of directors careers pipelineoliceridinetrv734trv250 platformable platformhistory of biased ligands investors press releases investor presentations analyst coverage corporate governance financials & filings stock information investor faqs contact us publicationstrv027oliceridinebiased ligand contactdirections copyright trevena inc. .